PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$6.71
+0.16 (+2.44%)
Open$6.65
Previous Close$6.55
Day High$7.08
Day Low$6.47
52W High$7.37
52W Low$3.01
Volume—
Avg Volume7.90M
Market Cap626.24M
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+152.6% upside
Current
$6.71
$6.71
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |
| Rev Growth | -3.3% | +11.1% | +4.4% |
| Debt/Equity | 0.58 | 0.61 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |